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We show that cryptdin-4 (Crp4), an antimicrobial peptide found in mice, induces the aggregation and hemi-fusion of charged phospholipid
vesicles constructed of the anionic lipid POPG and the zwitterionic lipid POPC. Hemi-fusion is confirmed with positive total lipid-mixing assay
results, negative inner monolayer lipid-mixing assay results, and negative results from contents-mixing assays. Aggregation, as quantified by
absorbance and dynamic light scattering, is self-limiting, creating finite-sized vesicle assemblies. The rate limiting step in the formation process is
the mixing of juxtaposed membrane leaflets, which is regulated by bound peptide concentration as well as vesicle radius (with larger vesicles less
prone to hemi-fusion). Bound peptide concentration is readily controlled by total peptide concentration and the fraction of anionic lipid in the
vesicles. As little as 1% PEGylated lipid significantly reduces aggregate size by providing a steric barrier for membrane apposition. Finally, as
stable hemi-fusion is a rare occurrence, we compare properties of Crp4 to those of many peptides known to induce complete fusion and lend
insight into conditions necessary for this unusual type of membrane merger.
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essential step in the ubiquitous process of membrane fusion within
biological systems. Events such as endo- and exocytosis,
fertilization, and even cellular infection by viruses, all require
the apposition of two or more lipid-enveloped entities. Similarly,
aggregation is also important within model membrane systems
such as vesicle or liposome suspensions. Here, it is often an
unwanted event, complicating fundamental studies designed to
probe the interactions of various membrane-active molecules with
lipid membranes. On the other hand, vesicle aggregation can be a
positive outcome, either as a precursor to desired fusion events or
simply as a means to purposefully segregate or condense soluble
membrane material.
Upon aggregation, vesicles may simply remain as individual
entities or they can unite and share lipids. When intermembrane
lipid-mixing occurs, two outcomes are possible. One is hemi-fused⁎ Corresponding author. Tel.: +1 609 258 4891; fax: +1 609 258 0211.
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doi:10.1016/j.bbamem.2007.04.016vesicles, where only the lipids within the outer membrane leaflets
of adjacent vesicles mix. The other is completely fused vesicles,
where both leaflets of adjacent membranes experience lipid-
mixing. Hemi-fusion maintains the interior aqueous regions of
each vesicle as separate compartments, while complete fusion
merges vesicle contents. Hemi-fusion is rarely a sustained state,
more often existing only as an intermediate step on the path to
complete fusion [1,2]. Though unusual, stable hemi-fused vesicles
may prove particularly useful for various applications, such as
multi-compartment drug delivery vehicles.
Aggregation is not usually a spontaneous process; it often
requires an aggregate-inducing agent. The identity of this agent
frequently determines if membrane and/or contents-mixing will
occur within the aggregated structure. Polymers such as
polyethylene glycol (PEG), multivalent ions like Ca+2, and
membrane-active peptides such as those found in viruses are
some of the most well studied aggregate-inducing agents. Both
PEG [3,4] and Ca+2 [5] have been found to cause complete
fusion of phospholipid vesicles. Peptides on the other hand,
exhibit a variety of behaviors. The α-helical peptide penetratin
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[6,7]. Other α-helical peptides, such as the influenza virus fusion
peptide [8–10] or the HIV fusion peptide [11,12], induce
complete fusion within biological and model membrane
systems, while a mutant of the influenza virus fusion peptide
has exhibited hemi-fusion inducing properties [13]. We note that
although many α-helical peptides share the ability to facilitate
aggregation/fusion among vesicle membranes, this trait is not
specific to that secondary structure. Fujii et al. have reported that
several β-sheet peptides found in humans and rabbits induce the
complete fusion of anionic membranes [14]. Also, myelin basic
protein, which can possess both a-helical and b-sheet portions,
induces the hemi-fusion of phospholipid vesicles [15].
Peptides bearing α-helical structure have been the subject of
numerous fusion studies [8,9,11,16–20], while the fusogenic
properties of peptides assuming aβ-sheet structure are still largely
unexplored. Membrane interactions of β-sheet peptides and α-
helical peptides are not expected to be similar, with differing
conformational changes, angles/depths of insertion, oligomeriza-
tion properties, etc. Hence, exploring the fusogenic abilities of β-
sheet peptides, and comparing them with those of α-helical
peptides, could lead to information regarding prerequisites for the
occurrence of fusion.
Of particular importance within the family of β-sheet peptides
is a class of peptides known as defensins. These peptides exist
within the innate immune system of mammals, plants, and insects,
and have been the subject of various membrane-interaction studies
[21–27]. The most well studied defensins include those isolated
from humans, rabbits, and mice. Several human and rabbit defen-
sins, as mentioned earlier, have been reported to cause complete
fusion within a system of anionic vesicles [14]. The fusogenic
properties ofmouse defensins, however, have never been explored.
In this paper, we examine the ability of the mouse defensin
cryptdin-4 (Crp4) to induce vesicle aggregation and membrane
fusion. This peptide is one of several cryptdins secreted by the
mouse small bowel and was found to be the most potent in
bactericidal assays conducted with Crp1–Crp6 [28]. Crp4
(sequence: GLLCYCRKGHCKRGERVRGTCGIRFLYCCPRR)
assumes a β-sheet structure stabilized by three disulfide bonds. It
has a molecular mass of about 3.8 kDa and possesses a large net
charge of +8.5 at physiological pH, a characteristic arising from its
high content of arginine residues. Here we show that Crp4 is
capable of inducing hemi-fused vesicle aggregates. The aggrega-
tion/hemi-fusion process can be controlled by altering vesicle size
as well as membrane composition. We also show how the
incorporation of lipid-anchored polyethylene glycol into the
vesicle membrane inhibits the aggregation/hemi-fusion process.
1. Materials and methods
1.1. Peptide
Cryptdin-4 was purchased from New England Peptide, Inc. (Gardner, MA).
The peptide was synthesized by solid phase peptide synthesis and was verified
by HPLC and amino acid analysis. Crp4 was N95% pure. Explicit tests were not
performed to determine if the folded structure of the peptide was correct.
However, bactericidal assays and membrane leakage assays performed with this
peptide and with Crp4 peptide from the research group of Andre Ouellette at theUniversity of California-Irvine, Department of Pathology and Laboratory
Medicine, showed identical results. The folded structure of the latter had been
confirmed. Therefore, due to the consistency of the assays with the two sets of





dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl)
(RH-DOPE), and 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[meth-
oxy(polyethylene glycol)-2000] (PEG2000-DPPE) were all purchased from
Avanti Polar Lipids (Alabaster, AL).
1.3. Chemicals and reagents
8-aminonaphthalene-1,3,6-trisulfonic acid (ANTS), p-xylene-bis-pyridi-
nium bromide (DPX), and 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindodicarbo-
cyanine-5,5'-disulfonic acid (DiIC18(5)-DS) were purchased from Molecular
Probes (Eugene, OR). Unless otherwise stated, all other chemicals were from
Sigma-Aldrich (St. Louis, MO), of the highest grade available, and used as
received. Water was produced by a Milli-Q UF unit (Millipore, Bedford, MA)
and had a resistivity of 18.2 MΩ-cm.
1.4. Preparation of liposomes
Small unilamellar vesicles (SUVs) were prepared by sonication of
multilamellar vesicle (MLV) dispersions for 1 h as performed with a VirTis
VirSonic 100 titanium tip sonicator. The MLV dispersions were formed by
hydrating dried lipid films (3 mL of buffer) and subjecting them to 5 cycles of
vortex-freeze–thaw.
Large unilamellar vesicles (LUVs) were prepared not by sonication, but
rather by extruding (Lipex Biomembranes Inc) the MLV dispersion twice
through a 400-nm (diameter) polycarbonate filter (Nucleopore Co.), followed by
10 times through either a 100-nm (diameter) or 300-nm (diameter)
polycarbonate filter, which generates vesicles of the nearly the same respective
size as determined using dynamic light scattering (DLS).
Giant unilamellar vesicles (GUVs) were created using a modification of the
electroformation method [29,30]. 50 μl of a 0.5-mg/ml lipid solution was spread
on platinum electrodes that were held 5 mm apart in a Teflon/glass cell. Films
were dried under vacuum overnight to remove trace solvent. An aqueous
solution was added to the cell, and vesicles were formed by the application of a
1.0-V sine wave across the electrodes.
Lipid concentrations were determined using a phosphorus assay explained in
a procedure made available by Avanti Polar Lipids (www.avantilipids.com).
1.5. Vesicle aggregation measurements
Kinetic absorbance measurements were employed to continuously monitor
vesicle aggregation. These measurements were carried out on a Spectronic
Genesys 2 UV-Vis spectrophotometer at 436 nm with a total sample volume of
2 ml. The lipid concentration of the sample was 50 μM while the peptide
concentration was adjusted according to the range of peptide to lipid molar ratios
studied. Dynamic light scattering experiments were performed using a
commercial apparatus [Brookhaven, Inc., BI-200SM laser light scattering
goniometer equipped with a solid-state laser (λ=532.5 nm) and an ALV-5000
correlator]. All measurements were performed at 25 °C under a scattering angle
of 90°. The lipid concentration of DLS samples was 1 mM, with peptide
concentrations adjusted so that the same peptide to lipid molar ratios were used
as in absorbance measurements.
1.6. Total lipid-mixing assay
Lipid-mixing was determined by a fluorescence resonance energy transfer
method using two lipid-anchored probes: NBD-DOPE and RH-DOPE [31]. In
short, the assay tracks the average separation of these two probes as lipid is
Fig. 1. Absorbance measurement of Crp4-induced vesicle aggregation. Samples
of POPG LUVs (∼100 nm diameter) at 50 μMwere created and Crp4 was added
to bring the peptide-to-lipid ratio in the samples to 0 (thin black line), 0.01 (thin
dark gray line), 0.02 (thin light gray line), 0.035 (thick black line), and 0.05
(thick dark gray line). Absorbance of the samples increases immediately
following the injection of Crp4 due to the creation of vesicle aggregates. Higher
concentrations of Crp4 induce greater aggregation.
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solutions are prepared for the assay: (1) POPG/POPC solution (this assay was
conducted at various ratios of the two lipids and exact ratios can be seen in
Results and the captions of Figs. 3 and 6) containing 0.8 mol% of each of the
fluorescently labeled lipids, (2) POPG/POPC solution of the same composition
but without the fluorescent lipids, and (3) POPG/POPC solution containing
0.08 mol% of each fluorescent lipid (calibration lipid solution). Lipid solutions
are dried under vacuum for 4 h and then, in the cases of SUVs and LUVs,
hydrated with an aqueous solution of 130 mM NaCl and 10 mM HEPES
(260 mOsm/L, pH 7.4). For creating GUVs, the dried lipid is hydrated with a
260-mM Glucose and 10 mM HEPES (260 mOsm/L, pH 7.4) solution but is
later diluted in the solution used for creating SUVs and LUVs. Aliquots from the
labeled and unlabeled vesicles are mixed at a 1:9 ratio to create a total lipid
concentration of 50 μM in a 2-ml volume. The excitation wavelength is set at
460 nm while the emission wavelength is set at 530 nm. The minimal
fluorescence originating from this solution is set as the 0% fluorescence. 100%
fluorescence is determined from a 50-μM solution of the calibration vesicles.
The fraction of lipid-mixing occurring as the result of the introduction of peptide
to the labeled and unlabeled vesicle solution is calculated as
Fraction of LipidMixing ¼ FðtÞ  Fo
Fl  Fo ð1Þ
where F(t) is the fluorescence intensity at time t, Fo is the minimal fluorescence,
and F∞ is the fluorescence of the calibration vesicles. The fluorescence
originating from a solution of calibration vesicles (F∞) remains constant even
after addition of peptide. The limiting value for a system undergoing full fusion
would be 1.0, and would be 0.5 if only hemi-fusion occurred (or somewhat
greater if the amounts of lipid on the inner and outer bilayer leaflets were not
equal).
1.7. Inner monolayer lipid-mixing assay
The general idea of this assay is to selectively label the inner monolayer of
vesicles with FRET pairs. This is accomplished by formulating vesicles with
probes throughout the membrane (i.e., on both monolayers) and then
incapacitating those residing in the outer leaflet with the addition of a reducing
agent [32]. As with the total lipid-mixing assay, monolayer mixing is revealed
by an increase in fluorescence as the FRET pairs change their average
separation. Three sets of lipid chloroform solutions are prepared for this assay:
(1) POPG solution containing 0.8 mol% NBD-DOPE and 0.8 mol% DiIC18(5)-
DS, (2) POPG only solution, and (3) POPG solution containing 0.08 mol%
NBD-DOPE and 0.08 mol% DiIC18(5)-DS (calibration lipid solution). Lipid
solutions are dried under vacuum for 4 h and LUVs (∼100 nm diameter) are
then created after hydrating the dried film with an aqueous solution of 130 mM
NaCl and 10 mM HEPES (260 mOsm/L, pH 7.4). Inner monolayer labeled
vesicles are created by adding sodium dithionite to preformed vesicles of (1) and
(3). Sodium dithionite eliminates the fluorescence originating from the outer
monolayer of the vesicles and reduces the sample fluorescence by approximately
50%. Excess sodium dithionite is removed from solution on a Sephadex G-50
column using a 130-mM NaCl and 10 mM HEPES (260 mOsm/L, pH 7.4)
aqueous solution as the eluant. Aliquots from (1) and (2), where (1) has been
exposed to sodium dithionite, are then mixed at a 1:9 ratio to create a total lipid
concentration of 50 μM in a 2-ml volume. The excitation wavelength is set at
460 nm while the emission wavelength is set at 530 nm. The minimal
fluorescence originating from this solution is set as 0% lipid-mixing. 100%
lipid-mixing is associated with the fluorescence of a 50-μM solution of (3) after
exposure to sodium dithionite. The fraction of lipid-mixing occurring as the
result of the introduction of peptide to the solution of (1) and (2) is calculated as
shown above for the total lipid mixing assay.
1.8. Contents-mixing assay
The mixing of the aqueous contents of vesicles was monitored with an assay
utilizing the fluorophore-quencher system of ANTS-DPX [31]. In short, this
assay tracks the decrease in fluorescence as ANTS-filled vesicles merge contents
with DPX-filled vesicles. Three identical lipid compositions of POPG and
POPC in chloroform are dried under vacuum for 4 h. Each of the lipid films isthen hydrated with one of the following solutions: (1) 25 mM ANTS, 90 mM
NaCl, 10 mM HEPES (260 mOsm/L, pH 7.4), (2) 90 mM DPX, 50 mM NaCl,
10 mM HEPES (260 mOsm/L, pH 7.4), (3) a 1:1 mixture of solutions 1 and 2.
LUVs are then created in the manner described above. Vesicles are separated
from unencapsulated fluorophore and quencher on a Sephadex G-50 column
using a 130-mM NaCl and 10 mM HEPES (260 mOsm/L, pH 7.4) aqueous
solution as the eluant. Equal amounts of ANTS-loaded and DPX-loaded vesicles
are mixed together to create a final lipid concentration of 50 μM in a 2-ml
volume. The fluorescence originating from this solution is the maximum
fluorescence, with the excitation wavelength of the spectrophotometer set at
360 nm while the emission wavelength is set at 530 nm. The fluorescence
generated by a 50-μM solution of ANTS-DPX-loaded vesicles is the minimum
fluorescence. Contents-mixing is calculated as
Fraction of ContentsMixing ¼ Io  IðtÞ
Io  Il ð2Þ
where I(t) is the fluorescence intensity at time t, Io is the maximum fluorescence,
and I∞ is the minimum fluorescence.2. Results
2.1. Turbidity
Turbidity, as described by absorbance, provides a numerical
measure of the degree of aggregation. Fig. 1 shows such time
dependent measurements as POPG LUVs (∼100 nm diameter)
are added to peptide at peptide to lipid molar ratios between 0
and 0.05. As can be seen, an increase in sample absorbance
occurs immediately following lipid injection, with higher ex-
tents correlated with higher concentrations of Crp4. The rate of
absorbance increase is initially fast but slows as aggregation
continues. After an hour, the absorbance readings appear to
have reached a stable value.
2.2. Dynamic light scattering
To further characterize the aggregation process, we employ
dynamic light scattering (DLS) to determine aggregate sizes.
POPG LUVs with radii of 47 nm, as measured using DLS, were
Fig. 2. DLS measurements of vesicle size. 1 mM solutions of POPG LUVs with
radii of 47 nm were subjected to Crp4 and allowed to incubate for 1 h. Aggregate
size increases with increasing peptide-to-lipid molar ratios until precipitates can
be seen settling out of solution at P/LN0.035. The dashed line demonstrates the
Arrhenius nature describing the size increase of vesicle aggregates.
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for 1 h, a time at which absorbance measurements suggest that
aggregate growth has stopped. Fig. 2 plots the stable aggregate
size as a function of peptide to lipid molar ratio. The dashed line
demonstrates the exponential scaling of aggregate size with P/L.
At P/L values greater than 0.035, precipitates can be seen forming
and settling out of solution.
We note thatDLS can produce erroneous datawhen extraneous
forces, such as those leading to vesicle aggregation, disturb the
natural Brownian motion of particles in solution. Our measure-
ments were made after aggregation had stabilized and therefore
should be indicative of the correct average hydrodynamic radius
of the aggregates, to the extent that they can be represented asFig. 3. Total lipid-mixing assay. Various concentrations of Crp4 were added to
50 μM solutions of POPG and 98.4 POPG/0.8 NBD-DOPE/0.8 RH-DOPE
LUVs (∼100 nm diameter). A change in the amount of quenching in the
fluorescently labeled vesicles is an indication of lipid-mixing and is quantified
as described in Materials and methods. Each black line in the inset is the
fluorescence spectrum of a system of vesicles where peptide is present at P/L
ratios of 0 to 0.05. The gray line is the fluorescence spectrum that would result if
100% lipid mixing occurred.spherical entities. At the very least, we get a qualitative trend
representative of how aggregate size is increasing with P/L.
2.3. Lipid-mixing and contents-mixing assays
Total lipid-mixing was monitored by following changes in
the amount of quenching between fluorescent lipid probes after
addition of Crp4 (as a result of redistribution of lipids between
vesicles (see Materials and methods)). The vesicle suspension
consisted of a 1:9 mixture of 98.4 POPG/0.8 NBD-DOPE/0.8
RH-DOPE:POPG. In Fig. 3, the fraction of total lipid-mixing is
plotted versus peptide to lipid molar ratio, revealing a direct
dependence of lipid-mixing on peptide concentration. The
fraction of total lipid-mixing reaches a value of ∼0.45 at a
P/L=0.05. This result affirms the occurrence of some level of
membrane fusion, whether it is hemi-fusion or complete fusion.
A second lipid-mixing assay, where the fluorescence from the
vesiclemembranes' outer monolayer is eliminated by the addition
of an aqueous reducing agent, reveals the extent of lipid mixing
between the inner monolayers of vesicles in solution. The vesicle
system utilized for this assay consisted of a 1:9 mixture of 98.4
POPG/0.8 NBD-DOPE/0.8 DiIC18(5)-DS:POPG. Shown in
Fig. 4A is the emission spectrum for vesicles before the probes
in the outer monolayer are incapacitated; Fig. 4B shows the
reduction in fluorescence upon adding the reducing agent sodium
dithionite. If peptide is added to these vesicles the spectra show no
change (black lines in Fig. 4 corresponding to 5 different P/L
values). As a point of reference we note that had inner monolayer
mixing occurred in all vesicles, Fig. 4C would represent theFig. 4. Inner monolayer lipid-mixing assay. Various concentrations of Crp4 were
added to 50 μM solutions of POPG and 98.4 POPG/0.8 NBD-POPE/0.8 DiIC18
(5)-DS LUVs (~100 nm diameter), where the fluorescence from the outer
monolayer of the latter had been eliminated by the addition of sodium dithionite.
Lipid-mixing is revealed by a change in the amount of quenching in the
fluorescently labeled vesicles. Curve A is the fluorescence spectrum from a
solution of vesicles where both monolayers of the labeled vesicles are
fluorescing. Curve B is the fluorescence spectrum of a solution of vesicles
where the fluorescence of the outer monolayer of the labeled vesicles has been
incapacitated (∼50% of curve A). The thin blank lines that coincide with curve
B are the resulting spectra when peptide at P/L ratios between 0.01 and 0.05 are
added to the vesicle solution represented by curve B. No change in quenching
(i.e., no lipid-mixing) is evident with addition of Crp4. Curve C is the
fluorescence spectrum that would result if 100% lipid-mixing occurred.
Fig. 5. Contents-mixing assay. 50 μM solutions of POPG LUVs (~100 nm
diameter) loaded with either ANTS or DPX were exposed to Crp4 (squares).
Quenching of the ANTS fluorescence by DPX reflects the occurrence of
contents-mixing. No contents-mixing occurred. Addition of Ca+2 to 50 μM
solutions of the same type of vesicles caused substantial contents-mixing after
only 15 min of incubation (diamonds).
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described in Materials and methods). This assay clearly indicates
that Crp4 induces only hemi-fusion (i.e., there is no inner
monolayer lipid mixing) at peptide to lipid ratios between 0 and
0.05.
To further confirm the occurrence of hemi-fusion, a contents-
mixing assay with POPG vesicles is employed to monitor any
mixing of internal vesicle components as a result of vesicle
exposure to Crp4. Contents-mixing is manifested by a decrease in
fluorescence intensity if vesicles encapsulating fluorescent cargo
(e.g., ANTS) merge contents with those containing quenchers
(e.g., DPX) (see Materials and methods). Fig. 5 shows that noFig. 6. Membrane composition dependence of lipid-mixing. LUVs (∼100 nm
diameter) were created of various ratios of anionic POPG and zwitterionic POPC
and mixed with Crp4. The non-linear scaling of lipid-mixing with membrane
composition (at constant P/L) is most likely a result of the non-linear scaling of
membrane charge with membrane composition. Symbols: 98.4 POPG/0.8 NBD-
DOPE/0.8 RH-DOPE (diamonds), 73.8 POPG/24.6 POPC/0.8 NBD-DOPE/0.8
RH-DOPE (squares), 49.2 POPG/49.2 POPC/0.8 NBD-DOPE/0.8 RH-DOPE
(triangles), 24.6 POPG/73.8 POPC/0.8 NBD-DOPE/0.8 RH-DOPE (circles),
98.4 POPC/0.8 NBD-DOPE/0.8 RH-DOPE (X's).contents-mixing occurs over the same P/L range where substantial
outer monolayer lipid-mixing occurs, corroborating the presence
of vesicle hemi-fusion within our system. We note that Ca+2, at
millimolar concentrations, exhibits the ability to induce complete
fusion of POPG vesicles and data for this process is also shown in
Fig. 5 to validate the null response obtained when peptide is added
to these same vesicles. Our previous researchwith Crp4 has shown
that this peptide can induce leakage of vesicle contents into the
extravesicular space to a degree that depends linearly on peptide
concentration, with only ∼50% contents released at P/L of 0.04
[33]. The leaked probes remain fluorescent because they are
diluted into the extravesicular solution; however if enough probe
remains in the vesicles quenching would still be observed in the
event of contents-mixing. Through independent control experi-
ments we have established that this assay is reliable if leakage is
b75%, as it is in our case. All told, the agreement of contents-
mixing assays and innermonolayer lipid-mixing assays (which are
not affected by leakage) gives full confidence in the finding of
peptide-induced hemi-fusion.
2.4. Effect of membrane composition
Lipid-mixing assays were conducted across a range of
vesicle membrane compositions as created by mixing the
anionic POPG with the zwitterionic POPC. Fig. 6 displays the
dependence of lipid-mixing on P/L at various POPG to POPC
ratios. The results show an increase in the degree of lipid-
mixing with increasing fraction of anionic lipid content.
Irrespective of membrane composition, each system exhibits a
direct dependence of lipid-mixing on the peptide to lipid ratio,
P/L.
2.5. Effect of vesicle curvature
POPG vesicles of various radii were created and used in
lipid-mixing assays. As measured by DLS, the vesicles studiedFig. 7. Vesicle radius dependence of lipid-mixing. POPG and POPG/NBD-
DOPE/RH-DOPE vesicles of various radii were created and subjected to Crp4.
As radius decreases, the vesicle membrane is more prone to contain defects,
thereby yielding more lipid-mixing upon introducing Crp4. Symbols: 15 nm
SUVs (diamonds), 47 nm LUVs (squares), 150 nm LUVs (triangles), 1872 nm
GUVs (circles).
Fig. 9. Effect of PEGylated lipid on Crp4-induced lipid-mixing. POPG LUVs
(diamonds) and POPG LUVs with 5% PEG2000-DPPE (squares) were created
(both∼100 nm diameter) and mixed with Crp4. As PEG2000-DPPE limits the
close approach of vesicles, the extent of lipid-mixing is attenuated accordingly.
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1872 nm (GUVs). The degree of lipid-mixing is inversely
dependent on the size of the vesicle membrane (Fig. 7). The
maximum fraction of lipid-mixing ranges from ∼0.20 for
GUVs to ∼0.60 for SUVs. We note that all SUV and LUV
suspensions were fairly monodisperse and had polydispersion
indices (PDIs) of 0.06 or less, while the GUV populations
contained vesicles with a wide range of diameters and had PDIs
as high as 0.45. We believe that the larger vesicles within the
GUV suspensions did not undergo lipid-mixing, whereas the
vesicles of smaller diameter did. This occurrence most likely
overestimates the actual amount of lipid-mixing that would occur
in a suspension of monodisperse GUVs (∼2 μm in radius).
Because SUVs show an increased propensity for lipid-mixing
over LUVs, contents-mixing assays were also conducted on
populations of SUVs to test for the occurrence of complete fusion.
Contents-mixing did not occur (data not shown). We note that
SUVs have a natural tendency to reassemble into larger vesicles
due to their thermodynamically unfavorable high membrane
curvature [34]. If complete fusion of SUVs did occur in our
system, wemay not havewitnessed a change in fluorescence of the
sample due to extensive vesicle leakage. However, we maintain
that Crp4 only causes their hemi-fusion. In any case, SUVs are not
ideal structures for lipid-mixing and contents-mixing assays due to
their inherently metastable nature.
2.6. Effect of lipid-anchored PEG
We have created vesicles containing various amounts of
PEGylated lipid for the purpose of observing how this polymer
affects the aggregation and hemi-fusion process induced by
Crp4. Absorbance measurements (Fig. 8) show that as little as
1% PEGylated lipid in POPG LUVs reduces absorbance by
nearly 80%, while increasing the percentage of PEGylated lipid
to 5% cuts absorbance by almost 95%. These data clearlyFig. 8. Effect of PEGylated lipid on Crp4-induced vesicle aggregation. POPG
LUVs (thick dark gray line) and POPG LUVs incorporating 1% (thick black line),
2% (thin light gray line), and 5% (thin dark gray line) PEG2000-DPPEwere created
(all ∼100 nm diameter) and exposed to Crp4 at a peptide-to-lipid ratio of 0.05.
Increasing amounts of PEG2000-DPPE led to a reduced sample absorbance due to
the ability of PEG2000-DPPE to restrict the apposition of vesicles.demonstrate that the inclusion of PEGylated lipid into POPG
vesicles diminishes the resulting aggregation upon introduction
of Crp4.
Results from lipid-mixing assays show that PEGylated lipid
in POPG LUVs also reduces the occurrence of membrane
merger as shown in Fig. 9. At 5% PEGylated lipid, the reduction
in lipid-mixing is as much as 75% (at P/L=0.05).
3. Discussion
Hemi-fusion of lipid vesicles is a process that involves the
mixing of lipids from the membranes of juxtaposed vesicles but
not mixing of the intervesicular contents. The data presented
show that Crp4 induces this process among anionic vesicles,
with P/L, membrane size, and membrane composition acting as
controlling variables. Careful inspection of the data presents
two questions meriting discussion: (1) What explains the
characteristics of the peptide induced aggregation process,
specifically the decay of the aggregation rate to zero and the
attainment of a stable aggregate size that increases with P/L?
and (2) What is special or different about Crp4–membrane
interactions that favor hemi-fusion over fusion?
In the simplest scenario, the formation of hemi-fused vesicle
aggregates consists of two steps: (1) the close apposition of
vesicle membranes and (2) the union of the outer monolayers of
those membranes leading to irreversible lipid-mixing. Vesicle
apposition (at constant vesicle concentration) is controlled by
Brownian motion (which is dependent upon vesicle size) and is
influenced by inter-vesicle forces, such as electrostatics and
hydration forces. Addition of the cationic peptide Crp4 to a
system of anionic POPG vesicles increases the vesicle collision
rate by attenuating the long-range electrostatic repulsion
existing between the negatively charged entities. In addition,
discrete charge–charge interactions at short-range (e.g., be-
tween a multivalent, positively charged peptide on one vesicle
and negative lipid on an adjacent vesicle) may also affect the
frequency of intimate collisions. Furthermore, binding of Crp4
to a vesicle membrane dehydrates the lipid headgroups, an
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of PEGylated lipid to vesicle membranes acts as a steric barrier
restricting the apposition of vesicle membranes and preventing
intermembrane contact as revealed in Figs. 8 and 9 [36–38].
It is reasonable to associate an activation energy with the
irreversible process of lipid-mixing, the second step in the for-
mation of hemi-fused aggregates, once themembranes are in close
apposition. The magnitude of this barrier is dependent on the
number of defects existing in the vesicle membrane (with more
defects yielding a smaller activation energy), consistent with the
work of others who have shown that increases in lipid-mixing
result from increased defect density [39,40]. Two distinct
mechanisms can generate membrane defects: (1) the inclusion of
membrane active agents such as antimicrobial peptides and (2)
curvature-induced membrane strain (smaller vesicles are more
likely to contain flaws in the membrane due to the strain placed
upon packing the lipids into such a tight radius of curvature
[12,39,41–44]). We have previously shown the capacity of our
peptide, Crp4, to destabilize membranes and induce defects with
the use of membrane leakage assays [33,45,46]. The extent of
membrane perturbation is directly proportional to the peptide
concentration as well as the anionic lipid content in the vesicle
membrane. Indeed, the extent of lipid-mixing is also proportional
to peptide concentration and fraction of anionic lipid (Figs. 3
and 6). With regard to size-induced defects, we find that lipid-
mixing increases as vesicle size decreases (Fig. 7).
Using this two step model of the aggregation/hemi-fusion
process, we are able to explain many features of the observed
system behavior. The increase of aggregation rate (Fig. 1) and
final aggregate size (Fig. 2) with P/L is a reflection of the lower
barrier height that results with an increase in the number of
membrane defects. Furthermore, the exponential dependence of
final aggregate size on P/Lmanifests the Arrhenius nature of the
hemi-fusion process (Fig. 2). The slowing of aggregation at a
given P/L leading to a steady-state aggregate size can be
associated with a decrease in collision frequency due to slowing
of Brownian motion as aggregate size increases; the rate of
lipid-mixing may also decrease as aggregate size increases due
to subtle changes in membrane curvature related to the hemi-
fusion process, as well as depletion of peptide due to translo-
cation (see below).
Within the context of a two step model, we can address the
issue of which step is rate controlling. Analysis of our absor-
bance data (Fig. 1) at time near zero (where the rate is highest),
yields an aggregation rate of 2.36e–16 m3/min at the highest P/
L examined (as derived using theory developed by Lichtenbelt
et al. to relate turbidity to aggregation rate of non-coalescing
particles [47]). This rate can be compared to that predicted by
Smoluchowski aggregation theory, where frequency of vesicle
collisions (step 1 in the model) determines the aggregation rate.
Assuming neutral particles, this predicted aggregation rate is
3.70e–16 m3/min and only slows to 3.63e–16 m3/min when
accounting for the potentials existing on anionic POPG vesicles
[48]. Clearly, this analysis shows that membrane union (step 2)
is the rate limiting step in the aggregation/hemi-fusion process.
Lastly, we can offer insight to explain the time scale over
which the aggregation rate changes significantly. The decay ofrate is likely associated with a molecular rearrangement process
occurring within our peptide–lipid system. Specifically, we
have recently discovered that Crp4 translocates across vesicle
membranes in a similar time scale over which aggregation
transpires (data to be published). Upon injection of vesicles into
peptide solution, binding occurs immediately to the outer
monolayer, after which the effective P/L decreases with time as
peptide distributes itself between both membrane leaflets. Con-
sequently, the defect density within the outer monolayer is
initially high and decreases with time, thus controlling the time
scale for aggregation.
Turning to the issue of why Crp4 causes hemi-fusion and not
complete fusion, we note that our experiments cannot answer
this question; however, we can provide insight by comparing
what is distinct about the interactions of Crp4 with lipid
membranes and those involving peptides that cause complete
fusion.
Several common features have been identified among the
many peptides that induce complete fusion. Typically, these
peptides contain a majority of hydrophobic residues, allowing
them to penetrate into the core of lipid membranes, most often
inserted in an oblique fashion [10,49–52]. Single amino acid
mutations lowering the hydrophobicity of these peptides or
altering their orientation of insertion have been found to
attenuate or even abolish fusion activity [9,17,53,54]. Crp4,
unlike these complete fusion-inducing peptides, is only about
38% hydrophobic and has been shown to reside in a super-
ficially bound state when interacting with lipid vesicles [45,55],
possibly lending to its ability to only induce hemi-fusion. As a
preliminary experiment, we tested the importance of hydropho-
bicity for inducing vesicle fusion by creating a hydrophobic
mutant of Crp4 where the five glycines in the primary sequence
were replaced by leucines. While this mutant did induce more
lipid-mixing, we still did not witness any occurrence of
contents-mixing (data not shown). These results indicate that
hydrophobicity may not be a critical determinant of fusogenic
ability, although much more work needs to be conducted to
validate this.
The ability to change conformation when binding to lipid
membranes is also a common trait among many fusion-inducing
peptides [8,56,57]. This change often involves a random coil to
α-helix transformation which maximizes favorable interaction
of the peptide with the membrane. It is highly unlikely that Crp4
undergoes any change in conformation, as its three disulfide
bridges rigidify the β-sheet structure of the peptide. Further-
more, merely the adoption of β-sheet structure may be
unconducive for eliciting complete fusion. Experiments with
peptides subjected to mutations that disrupt the formation of
α-helical structure in favor of a β-sheet structure have shown
that these changes were accompanied by a loss of fusogenicity
[58–60]. Fujii and coworkers have stated that several human
and rabbit defensins, all with β-sheet structure, can induce
complete fusion [14]; however, it must be noted that this
conclusion was reached only after conducting lipid-mixing
assays and not contents-mixing assays, confirming only one of
the two requirements for complete fusion. Nieva and coworkers
showed that the HIV fusion peptide induces complete vesicle
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presence of Ca+2 or Mg+2, two known fusogenic agents, were
required [11,61].
Another common feature among fusion-inducing peptides is
their tendency to oligomerize. Furthermore, these oligomerized
structures are most often trimers or other higher order
assemblies [62–64]. Peptides devoid of fusion activity often
lack the ability to assemble into oligomers, or only oligomerize
to the extent of dimer formation [16,18,65]. NMR studies with
Crp4 have shown that this peptide exists as monomers in
solution; the membrane bound organization of Crp4 has yet to
be determined [66]. Although we have no direct experimental
data to determine oligomerization, lipid-mixing data and
peptide-induced vesicle leakage data [33,45,46] all scale
directly with peptide concentration (and not to a power thereof),
consistent with an uncooperative process.
In summary, our survey of the literature shows that most
fusogenic peptides possess the following characteristics: largely
hydrophobic (N50%), exhibit membrane-induced conforma-
tional changes to α-helices, and undergo oligomerization. As
Crp4 does not embody these characteristics, it is not surprising
that complete fusion is not observed. Exactly why these
characteristics promote complete fusion, instead of hemi-fusion,
or no fusion, remains an open and interesting question. Equally
compelling is the question of what peptide properties are
necessary to induce only hemi-fusion, a rarely witnessed
occurrence. In the case of Crp4, the peptide is both superficially
bound (i.e., limited penetration into the hydrophobic core of the
membrane) and is slow to translocate (to be published). This
combination leads to a prolonged imbalance in strain across the
membrane (from one leaflet to the next), which may impart the
elusive conditions for hemi-fusion.
4. Conclusion
We have shown that the β-sheet peptide Crp4 is capable of
inducing hemi-fused vesicle aggregates, an uncommonmembrane
microstructure. We have determined that the rate limiting step in
the formation process is the union of juxtaposed vesicle
membranes, which is an activated process dependent upon mem-
brane defects as regulated by peptide concentration and vesicle
radius. A large degree of control over the aggregation/hemi-fusion
process is afforded through manipulation of variables such as
membrane charge,membrane composition (e.g., PEGylated lipid),
vesicle concentration, and, as mentioned previously, peptide con-
centration and vesicle size.
Our findings shed new light on the membrane interactions of
Crp4 and may even lend insight into the properties of a peptide
necessary for inducing hemi-fusion of lipid membranes. The
discovery that Crp4 can induce a sustained hemi-fused state of
anionic lipid vesicles is one that provokes many ideas for use
in practical applications, one of those being the possibility to
create multi-compartment vesicular structures for use as drug
delivery agents. Presently, hemi-fusion is a rarely witnessed
occurrence, but as the membrane interactions of more β-sheet
peptides are studied, hemi-fusion may prove to be a more
pervasive process.Acknowledgement
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